We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11B
AUM Growth
+$1.48B
Cap. Flow
-$1.03B
Cap. Flow %
-9.36%
Top 10 Hldgs %
83.4%
Holding
140
New
7
Increased
14
Reduced
16
Closed
6

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.6M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$44.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$40.8M
4
NGNE icon
Neurogene
NGNE
+$28.1M
5
EXEL icon
Exelixis
EXEL
+$25.4M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$24.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$19.9M
3
NVAX icon
Novavax
NVAX
+$17.3M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$16.2M
5
INSM icon
Insmed
INSM
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.07%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
101
DELISTED
Acceleron Pharma
XLRN
$1.04M 0.01%
28,765
– –
FPRX
102
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$1.01M 0.01%
19,247
– –
TENX icon
103
Tenax Therapeutics
TENX
$65.5M
$972K 0.01%
13
– –
SVRA icon
104
Savara
SVRA
$1.15B
$944K 0.01%
122,629
+67,371
+122% +$1.91M
APTO
105
DELISTED
Aptose Biosciences, Inc.
APTO
$909K 0.01%
+898
New +$934K
INFI
106
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$905K 0.01%
+580,400
New +$892K
DVAX
107
DELISTED
Dynavax Technologies
DVAX
$787K 0.01%
75,000
– –
ALNY icon
108
Alnylam Pharmaceuticals
ALNY
$31.6B
$769K 0.01%
11,340
– –
MDGL icon
109
Madrigal Pharmaceuticals
MDGL
$11.9B
$732K 0.01%
57,762
-2
-0% -$19
ADAP
110
DELISTED
Adaptimmune Therapeutics
ADAP
$705K 0.01%
100,000
– –
AIXC
111
AIxCrypto Holdings Inc
AIXC
$22.7M
$672K 0.01%
3
– –
WINT
112
DELISTED
Windtree Therapeutics Inc
WINT
$653K 0.01%
254,973
– –
CMRX
113
DELISTED
Chimerix, Inc.
CMRX
$638K 0.01%
115,216
– –
ABUS icon
114
Arbutus Biopharma
ABUS
$1.03B
$621K 0.01%
180,582
– –
ABEO icon
115
Abeona Therapeutics
ABEO
$348M
$610K 0.01%
+4,067
New +$398K
BDSI
116
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$567K 0.01%
210,021
– –
FMI
117
DELISTED
Foundation Medicine, Inc.
FMI
$488K ﹤0.01%
20,892
– –
AKAO
118
DELISTED
Achaogen Inc
AKAO
$479K ﹤0.01%
100,000
– –
CYTR
119
DELISTED
CytRx Corp
CYTR
$388K ﹤0.01%
109,999
– –
SRRA
120
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$364K ﹤0.01%
5,000
– –
LJPC
121
DELISTED
La Jolla Pharmaceutical Company
LJPC
$327K ﹤0.01%
13,746
– –
CCXI
122
DELISTED
ChemoCentryx, Inc.
CCXI
$296K ﹤0.01%
49,064
– –
BGMSP
123
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$90K ﹤0.01%
13,253
– –
BTX.WS
124
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$17K ﹤0.01%
20,084
– –
AUPH icon
125
Aurinia Pharmaceuticals
AUPH
$2.22B
– –
-711,499
Closed -$2.12M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2016 Portfolio in Review

As of Q3 2016, Julian Baker held 140 positions worth $11B, up 16% from $9.54B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.03B in Q3 2016, closing 6 positions and reducing 16 holdings. Its most notable exit was XENOPORT, INC., an estimated $24.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Technology.

Against the trend, Julian Baker opened a new position in ContraFect Corporation worth $10M.

  • Julian Baker's largest Q3 2016 buy was ContraFect Corporation: 5,057 shares worth $10M.
  • Julian Baker added most to Amarin Corp in Q3 2016, an estimated $55.6M increase.
  • Julian Baker's biggest Q3 2016 reduction was BioCryst Pharmaceuticals, cutting an estimated $16.2M.
  • Julian Baker fully exited XENOPORT, INC. in Q3 2016, selling an estimated $24.5M.
  • Julian Baker's ten largest holdings make up 83% of its $11B portfolio in Q3 2016.
  • Julian Baker opened 7 new positions and closed 6 in Q3 2016.
  • Julian Baker's portfolio value rose 16% quarter-over-quarter to $11B.

Based on Baker Bros. Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.